A Trial of Indomethacin in Acute Pancreatitis
A Trial of Indomethacin in Acute Pancreatitis
Acute pancreatitis (AP) is an inflammatory condition of the pancreas following the activated
 pancreatic enzymes induced by varied causes, with or without other organ(s) dysfunction. The
 production and release of inflammatory factors is generally considered as the key factor of
 pathogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly applied
 agents for inflammatory diseases. A series studies have proved that indomethacin can reduce
 the risk of post-endoscopic retrograde cholangiopancreatography (ERCP), but high-quality
 evidence is still lacking in the field of effectiveness of NSAIDs to treat, rather than
 prevent, other types of AP. Majority of animal experiments showed that NSAIDs had protective
 effects for organ functions, but the results of several preliminary clinical studies were
 inconsistent. Randomized controlled trials are eagerly awaited to elucidate its effects on
 AP.
Inclusion Criteria:

 -  All patients ages 18-75 years admitted to Peking Union Medical College Hospital
 (PUMCH) with a diagnosis of AP based on at least 2 of the following criteria:

 -  Abdominal pain characteristic of AP

 -  Serum amylase and/or lipase ≥ 3 times the upper limit of normal

 -  Characteristic findings of AP on abdominal CT scan will be screened for study
 enrollment.

 Exclusion Criteria:

 -  Onset time >48 hours

 -  Presence of renal dysfunction (serum creatinine > 1.5 *normal upper limit)

 -  Active peptic ulcer disease or GI bleeding

 -  Pregnancy or breast-feeding

 -  Use of daily antiplatelet or anticoagulant drug(s) within 2 week of presentation

 -  Hypersensitivity to NSAIDs

 -  New-onset, exacerbation or uncontrolled hypertension

 -  Presence of serious cardiovascular events, including severe heart failure, myocardial
 infarction (MI) and stroke

 -  Mental disability